Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221768 | 0.85 | UNG (0.56) | MAPTHTTTP53 | |
| SCHEMBL5309531 | 0.83 | TP53 (0.63) | MAPTHTTTP53 | |
| SCHEMBL8154153 | 0.83 | GPR84 (0.53) | MAPTHTT | |
| SCHEMBL21221793 | 0.83 | MAPT (0.61) | MAPTHTTTP53 | |
| SCHEMBL21234494 | 0.82 | UNG (0.55) | — | |
| SCHEMBL5298937 | 0.81 | TP53 (0.71) | MAPTHTTTP53 | |
| SCHEMBL21221811 | 0.81 | TP53 (0.61) | MAPTHTTTP53 | |
| SCHEMBL21221877 | 0.81 | MAPT (0.68) | MAPTHTTTP53 | |
| SCHEMBL20402856 | 0.81 | MAPT (0.62) | MAPTHTTTP53 | |
| SCHEMBL4743077 | 0.81 | MAPT (0.48) | MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144796-A1 | Compounds and Methods for Improving Health | Acurx Pharmaceuticals, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4587028-A2 | COMPOUNDS AND METHODS FOR IMPROVING HEALTH | Acurx Pharmaceuticals, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120202009-A | Compounds and methods for improving health | 阿科利斯制药股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | ACURX PHARMACEUTICALS LLC (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | ACURX PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-08-08 | — | — | US | disclosed |
| WO-2018209343-A1 | NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS: SMALL MOLECULE ANTICANCER AGENTS | RAJUR SHARANAPPA BASAPPA (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2002103039-A1 | A METHOD FOR MEASURING DNA POLYMERIZATION AND APPLICATIONS OF THE METHOD | CAVIDI TECH AB (SE) | 2002-12-27 | — | — | WO | disclosed |
| US-6448256-B1 | PRECURSORS OF N-SUBSTITUTED DERIVATIVES OF 6-AMINOURACILS, 6-AMINOISOCYTOSINES, GUANINES AND 2-AMINOADENINES HAVING A CLEAVABLE ESTER GROUP; GREATER WATER SOLUBILITY AND ORAL BIOAVAILABILITY; TREATING GRAM POSITIVE BACTERIAL INFECTIONS | UNIVERSITY OF MASSACHUSETTS | 2002-09-10 | — | — | US | disclosed |
| EP-1185517-A1 | ANTIBIOTIC PRODRUGS | University of Massachusetts (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6177437-B1 | VIRICIDES | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER | 2001-01-23 | — | — | US | disclosed |
| WO-2000071523-A1 | ANTIBIOTIC PRODRUGS | UNIVERSITY OF MASSACHUSETTS (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0772439-B1 | Novel antibiotic compounds and antibiotic compositions comprising said compounds for inhibiting gram positive bacteria and mycoplasma cells. | UNIV MASSACHUSETTS MEDICAL (US) | 2000-10-04 | — | — | EP | disclosed |
| US-4997818-A | Using a nitrogenous heterocyclic base and dideoxy-pentose monosaccharides | THE UNIVERSITY HOSPITAL (US) | 1991-03-05 | — | — | US | disclosed |
| WO-1988004658-A1 | 10-(SUBSTITUTED PHENYL)-3-ALKYLFLAVIN DERIVATIVES HAVING ANTIPROTOZOAL, ANTIPROLIFERATIVE AND ANTIINFLAMMATORY ACTIVITY | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1988-06-30 | — | — | WO | disclosed |
| US-4576948-A | Composition and method for inhibiting terminal deoxyribonucleotidyl transferase activity | TRUSTEES BOSTON UNIVERSITY (US) | 1986-03-18 | — | — | US | disclosed |
| WO-1982004192-A1 | COMPOSITION AND METHOD FOR INHIBITING TERMINAL DEOXYRIBONUCLEOTIDYL TRANSFERASE ACTIVITY | MCCAFFREY RONALD | 1982-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144796-A1 | Compounds and Methods for Improving Health | POLN, POLH, POLB | MAPT 2502/4885HTT 1940/4885TP53 1531/4885 |
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | ABCC1, MCL1, ABCC3 | MAPT 4452/4885HTT 4254/4885TP53 8/4885 |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | MAPT 3107/4885HTT 3270/4885TP53 1304/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | MAPT 4346/4885HTT 4437/4885TP53 2281/4885 |
| US-20220024925-A1 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | DUT, DCTD, TPMT | MAPT 3908/4885HTT 4449/4885TP53 4131/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | MAPT 3107/4885HTT 3270/4885TP53 1304/4885 |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | ABCC1, MCL1, ABCC3 | MAPT 4452/4885HTT 4254/4885TP53 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.